Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 202Recurrence 53Neoplasms, Plasma Cell 19Neoplasms 12Immunoglobulin Light-chain Amyloidosis 10Hematologic Diseases 4Amyloidosis 4Renal Insufficiency 3Lymphoma, Non-Hodgkin 3Blood Protein Disorders 3Plasmacytoma 2Paraproteinemias 2Neoplasms by Histologic Type 2Disease Progression 2Chromosome 17 deletion 2Waldenstrom Macroglobulinemia 1Smoldering Multiple Myeloma 1Proteostasis Deficiencies 1Malignant Plasma Cell Neoplasms 1Lymphoma, T-Cell, Peripheral 1Leukemia, Plasma Cell 1Leukemia, Myeloid, Acute 1Hypoxia 1Hodgkin Disease 1Hematologic Neoplasms 1Disease 1Corneal Diseases 1Alzheimer Disease 1

Interventions

Dexamethasone 4selinexor 1pomalidomide 1ixazomib 1birtamimab 1Positron-Emission Tomography 1Melphalan 1Cyclophosphamide 1Calcium Dobesilate 1Bortezomib 1Blood Specimen Collection 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Alzheimer Disease × pomalidomide × Plasma cell × Clear all
NCT04270175 2026-02-27

Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab

Weill Medical College of Cornell University

Phase 2 Active not recruiting
15 enrolled
Plasma cell

Immunoglobulin Light-chain Amyloidosis, Alzheimer Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡